Want to see RHHBY full AI Analyst Report?
RHHBY Stock Chart & Stats
$51.27
$0.20(0.55%)
At close: 4:00 PM EST
$51.27
$0.20(0.55%)
Day’s Range― - ―
52-Week Range$37.51 - $60.85
Previous CloseN/A
Volume3.10M
Average Volume (3M)2.23M
Market Cap
$315.55B
Enterprise Value$286.98B
Total Cash (Recent Filing)$15.49B
Total Debt (Recent Filing)$33.19B
Price to Earnings (P/E)19.7
Beta0.35
Next Earnings
Jul 23, 2026EPS Estimate
1.59Next Dividend Ex-DateN/A
Dividend Yield1.63%
Share Statistics
EPS (TTM)1.43
Shares Outstanding5,620,501,500
10 Day Avg. Volume1,607,563
30 Day Avg. Volume2,230,209
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)7.76
Price to Sales (P/S)4.15
P/FCF Ratio19.53
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue6.21
Enterprise Value/Gross Profit8.49
Enterprise Value/Ebitda13.22
Forecast
1Y Price Target
$56.00Price Target Upside9.23% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)3.16
Revenue Forecast (FY)$79.11B
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsEarly trontinemab data shows competitive amyloid clearance and improved ARIA rate versus peers, but clinical outcomes will determine success.
Financial PerformanceRoche's model was updated and numbers raised post recent business trends, with sales and EPS growth estimates increased.
Product EfficacyGazyva showed potential best-in-class profile in lupus nephritis and is likely to be the starter therapy of choice versus GSK's Benlysta.
Bears Say
Clinical Trial SafetyThere was a case of fatal cerebral macrohemorrhage in Part 2, leading to updated trial criteria to exclude patients with superficial siderosis.
Placebo ResponseThe high placebo response rate in males was notable, where placebo achieved a 66.7% complete renal response compared to 42.9% for Gazyva.
Roche Holding News
RHHBY FAQ
What was Roche Holding AG’s price range in the past 12 months?
Roche Holding AG lowest stock price was $37.51 and its highest was $60.85 in the past 12 months.
What is Roche Holding AG’s market cap?
Roche Holding AG’s market cap is $315.55B.
When is Roche Holding AG’s upcoming earnings report date?
Roche Holding AG’s upcoming earnings report date is Jul 23, 2026 which is in 17 days.
How were Roche Holding AG’s earnings last quarter?
Roche Holding AG released its earnings results on Jan 29, 2026. The company reported $1.361 earnings per share for the quarter, beating the consensus estimate of $1.341 by $0.02.
Is Roche Holding AG overvalued?
According to Wall Street analysts Roche Holding AG’s price is currently Undervalued.
Does Roche Holding AG pay dividends?
Roche Holding AG pays a Annually dividend of $1.55 which represents an annual dividend yield of 1.63%. See more information on Roche Holding AG dividends here
What is Roche Holding AG’s EPS estimate?
Roche Holding AG’s EPS estimate is 1.59.
How many shares outstanding does Roche Holding AG have?
Roche Holding AG has 5,620,501,500 shares outstanding.
What happened to Roche Holding AG’s price movement after its last earnings report?
Roche Holding AG reported an EPS of $1.361 in its last earnings report, beating expectations of $1.341. Following the earnings report the stock price went up 4.837%.
Which hedge fund is a major shareholder of Roche Holding AG?
Currently, no hedge funds are holding shares in RHHBY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Roche Holding Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$56.00 (9.23% Upside)
$56.00 (9.23% Upside)
Blogger Sentiment
Bullish
RHHBY Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.42%
12-Months-Change
Fundamentals
Return on Equity
41.23%
Trailing 12-Months
Asset Growth
13.16%
Trailing 12-Months
Company Description
Roche Holding AG
Roche Holding AG functions as a major global healthcare enterprise, primarily concentrating its efforts within the pharmaceutical and diagnostic sectors. The company boasts an extensive international presence, with key operations located in countries such as Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium. Its pharmaceutical division is dedicated to creating and supplying a diverse array of therapeutic remedies. These target a broad spectrum of medical fields, including oncology, neuroscience, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory ailments. The comprehensive product line further extends to treatments for specific conditions like infectious diseases, anemia, various dermatological issues, hemophilia, inflammatory and autoimmune disorders, neurological conditions, and transplantation-related needs. Within its diagnostics segment, Roche develops and markets a wide variety of laboratory-based tests designed to identify and monitor numerous illnesses. These include, but are not limited to, cancer, diabetes, Covid-19, hepatitis, and human papillomavirus. Additionally, the company is a provider of essential diagnostic instruments and reagents. Established in 1896, Roche Holding AG maintains its corporate headquarters in Basel, Switzerland.
RHHBY Stock 12 Month Forecast
Average Price Target
$56.00
▲(9.23% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.54% Mutual Funds
<0.01% Other Institutional Investors
99.42% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---